Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRF312 5% in Dry Eye Disease
NCT07264517Phase 2Completed
- Sponsor
- Grifols
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GRF312 in dry eye disease (DED), sponsored by Grifols. Started Nov 2025; status: completed.
02
Drugs
GRF312
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07264517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264517.